No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.0x · 10Y median 2.0x · 79th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:27:46.230Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Metagenomi, Inc. Common Stock (MGX) stock was $1.07 as of Oct 6, 2026, 11:23 AM EDT, up 2.88% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -60.6%
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients.
Biotechnology · Emeryville, CA
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-0.64
Revenue Est.
$2.58M
Last Quarter Results
EPS
$-0.73
vs Estimate
$-0.52
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MGX | $40.28M | $1.07 | +2.88% | -60.58% | N/A | N/A | N/A |
| 2NEPH | $39.90M | $3.67 | +3.52% | -25.47% | -15.93% | +1.80% | vs MGX |
| 3HBIO | $39.33M | $8.72 | +2.59% | +88.73% | -34.33% | -11.05% | vs MGX |
| 4FLNA | $41.77M | $0.86 | -0.59% | N/A | N/A | N/A | vs MGX |
| 5PRPO | $41.92M | $23.50 | -2.08% | +15.42% | -14.46% | N/A | vs MGX |
| 6IXHL | $38.35M | $3.21 | -0.16% | -77.63% | N/A | N/A | vs MGX |
forward FY estimate
N/A
$-257000.00
vs Estimate
$3.01M
Consensus Rating
Based on 3 analysts
Average Price Target
$7.00
+554.2% upside
Low
$5.00
Current
$1.07
High
$9.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.65 | $-0.64 | $-0.63 | 3 |
| Quarter ending Dec 2026 | $-0.78 | $-0.56 | $-0.35 | 3 |
| Quarter ending Mar 2027 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Quarter ending Jun 2027 | $-0.47 | $-0.47 | $-0.47 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.79 | $-2.49 | $-2.15 | 3 |
| FY 2027 | $-2.19 | $-1.88 | $-1.67 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.58M | $2.58M | $2.58M | 3 |
| Quarter ending Dec 2026 | $2.58M | $2.58M | $2.58M | 3 |
| Quarter ending Mar 2027 | $2.65M | $2.65M | $2.65M | 1 |
| Quarter ending Jun 2027 | $2.65M | $2.65M | $2.65M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.33M | $5.11M | $8.88M | 3 |
| FY 2027 | $4.88M | $9.34M | $13.64M | 3 |
